We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Fetal Alcohol Syndrome Determined by Examining First Stool

By Labmedica staff writers
Posted on 19 Mar 2008
Measuring the levels of fatty acid ethyl esters (FAEE) in an infant's first bowel movement could be a useful method for identifying children at risk for fetal alcohol syndrome (FAS), which may make early intervention possible.

Children who have been diagnosed with FAS are more likely to have serious psychiatric and behavioral problems later in life, including a higher risk for dropping out of school, unemployment, and criminal behavior. More...
Studies have shown that early intervention is a key element in minimizing the negative effects of FAS. Early diagnosis of FAS is not always possible, especially if certain physical characteristics are not present. A study was performed aiming to develop a new way to diagnose infants affected by FAS.

A group of 216 infants whose mothers drank various amounts of alcohol during pregnancy was studied. The levels of FAEE, which are produced when alcohol is broken down in the digestive system, were measured in the first bowel movement of the newborns. The babies were then given developmental tests at the ages of six months, one year, and two years.

Infants with higher levels of FAEE in their first bowel movement were found to be at risk for developmental disorders. According to investigator Dr. Jennifer Peterson, currently at the Cleveland Clinic (Cleveland, OH, USA), "increasing levels of FAEE were significantly associated with poorer mental and psychomotor development during the first two years of life. She also noted, early intervention for such at risk children could minimize disabilities and improve developmental outcomes.”


Related Links:
Cleveland Clinic

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.